Laboratory Benefit Management (LBM) Policies
Effective July 1, 2024, Presbyterian implemented a new Laboratory Benefit Management (LBM) program with the goal of providing high-quality healthcare at the most affordable costs. All policies are directed at enforcing correct billing guidelines and are listed below.
Additional Resources
- Administrative Claims Edits Guide Summary of Updates
- Laboratory Benefit Management FAQ
- Reimbursement (Laboratory Procedures Reimbursement Policy), AHS-R2162
A
- Allergen Testing, AHS-G2031
- Alpha-1 Antitrypsin Deficiency, Testing for, AHS-M2068
- Alzheimer Disease and Dementia, Biochemical Markers of, AHS-G2048
- Autoimmune Rheumatic Disease, Biomarker Testing for, AHS-G2022
B
- Beta-Hemolytic Streptococcus Testing, AHS-G2159
- Bone Turnover Markers Testing, AHS-G2051
- Brain Injury (Serum Testing for Evidence of Mild Traumatic Brain Injury), AHS-G2151
C
- Cardiovascular Disease Risk Assessment, AHS-G2050
- Celiac Disease Testing, AHS-G2043
- Cervical Cancer Screening, AHS-G2002
- Colorectal Cancer Screening, AHS-G2181
- Coronavirus Testing in the Outpatient Setting, AHS-G2174
D
E
F
- Fecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing, AHS-G2060
- Flow Cytometry, AHS-F2019
- Folate Testing, AHS-G2154
G
H
- Helicobacter pylori Testing, AHS-G2044
- Hepatitis Testing, AHS-G2036
- Homocysteine Metabolism-Related Conditions, Testing of, AHS-M2141
- Human Immunodeficiency Virus (HIV), AHS-M2116
I
- Idiopathic Environmental Intolerance, Diagnosis of, AHS-G2056
- Immune Cell Function Assay, AHS-G2098
- Immunohistochemistry, AHS-P2018
- Inflammation Testing, General, AHS-G2155
- Inflammatory Bowel Disease, Laboratory Testing for the Diagnosis of, AHS-G2121
- Influenza, Diagnostic Testing of, AHS-G2119
- Intracellular Micronutrient Analysis, AHS-G2099
- In Vitro Chemoresistance and Chemosensitivity Assays, AHS-G2100
- Iron Homeostasis & Metabolism, Diagnostic Testing of, AHS-G2011
L
- Liver Disease (Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease), AHS-G2110
- Lyme Disease Testing, AHS-G2143
M
- Multiple Sclerosis and Related Neurologic Diseases, Serum Biomarker Testing for, AHS-G2123
- Myocardial Infarction and Chronic Heart Failure, Biomarkers for, AHS-G2150
N
- Nerve Fiber Density Testing, AHS-M2112
- Nucleic Acid Probes (Identification of Microorganisms Using Nucleic Acid Probes), AHS-M2097
O
P
- Pancreatic Enzyme Testing for Acute Pancreatitis, AHS-G2153
- Parathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing, AHS-G2164
- Pathogen Panel Testing, AHS-G2149
- Pediatric Preventive Screening, AHS-G2042
- Prenatal Screening (Nongenetic), AHS-G2035
- Prescription Medication and Illicit Drug Testing in the Outpatient Setting, AHS-T2015
- Prostate Biopsy Specimen Analysis, AHS-G2007
- Prostate Specific Antigen (PSA) Testing, AHS-G2008
S
- Salivary Hormone Testing, AHS-G2120
- Sexually Transmitted Infections (Diagnostic Testing of Common Sexually Transmitted Infections), AHS-G2157
T
- Testosterone, AHS-G2013
- Therapeutic Drug Monitoring for 5-Fluorouracil, AHS – M2067
- Therapeutic Serum Antibodies, Immunopharmacologic Monitoring of, AHS-G2105
- Thiopurines Testing, Metabolite Markers for, AHS-G2115
- Thyroid Disease Testing, AHS-G2045
- Tuberculosis (Testing for Diagnosis of Active or Latent Tuberculosis), AHS-G2063
- Tumor Markers for Malignancies, Serum, AHS-G2124
